Cargando…

Association of COVID-19 with Disability Progression and Disease Exacerbation in People with Relapsing-Remitting Multiple Sclerosis: Evidence from a Year-Long Observational Study

Detalles Bibliográficos
Autores principales:	Sedaghat, Nahad, Etemadifar, Masoud, Nouri, Hosein, Abhari, Amir Parsa, Maleki, Shiva, Amin, Alireza, Salari, Mehri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765397/ http://dx.doi.org/10.1016/j.msard.2022.103589

Ejemplares similares

Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2023)

Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis
por: Etemadifar, Masoud, et al.
Publicado: (2022)

COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Successful seroconversion following mild COVID-19 contraction in a double-vaccinated B-cell-depleted person with multiple sclerosis: A hint towards booster efficacy?
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Multiple sclerosis in sarcoidosis patients: Two case reports
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Movement Disorders Associated with COVID-19
por: Salari, Mehri, et al.
Publicado: (2021)

Post-COVID-19 acute disseminated encephalomyelitis: Case report and review of the literature
por: Etemadifar, Masoud, et al.
Publicado: (2022)

SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Epidemiological and clinical features of pediatric-onset multiple sclerosis: A population-based study in Isfahan, Iran, between 1997-2020
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity
por: Sedaghat, Nahad, et al.
Publicado: (2023)

Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study
por: Tabrizi, Nasim, et al.
Publicado: (2012)

Myasthenia gravis and coronavirus disease 2019: A report from Iran
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study
por: Sedaghat, Nahad
Publicado: (2021)

The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population
por: Abdar, Morteza, et al.
Publicado: (2016)

Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study
por: Etemadifar, Masoud, et al.
Publicado: (2011)

Cooccurrence of Chorea-Acanthocytosis and Mesial Temporal Sclerosis: A Possible Role of Caudate Nucleus
por: Salari, Mehri, et al.
Publicado: (2017)

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
por: Daruwalla, Cyrus, et al.
Publicado: (2023)

Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model
por: Najarzadegan, Niloofar, et al.
Publicado: (2022)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Interferon beta-1b-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) in a patient treated for multiple sclerosis: A case report
por: Etemadifar, Masoud, et al.
Publicado: (2018)

Complete horizontal gaze palsy due to bilateral paramedian pontine reticular formation involvement as a presentation of multiple sclerosis: a case report
por: Akhavan Sigari, Amirhossein, et al.
Publicado: (2019)

WITHDRAWN: Incidence and mortality of COVID-19 in Iranian multiple sclerosis patients treated with disease-modifying therapies
por: Etemadifar, M., et al.
Publicado: (2020)

Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases
por: Etemadifar, Masoud, et al.
Publicado: (2011)

Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
por: Cadavid, Diego, et al.
Publicado: (2013)

Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability
por: Migliore, S., et al.
Publicado: (2017)

Can COVID‐19 accelerate neurodegeneration?
por: Salari, Mehri, et al.
Publicado: (2021)

Systemic Sclerosis, Reversible Cerebral Vasoconstriction Syndrome, and NeuroMyelitis Optica in a Patient
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
por: Doosti, Rozita, et al.
Publicado: (2021)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials
por: Lavery, Amy M., et al.
Publicado: (2014)

Intrinsic Functional Plasticity of the Thalamocortical System in Minimally Disabled Patients with Relapsing-Remitting Multiple Sclerosis
por: Zhou, Fuqing, et al.
Publicado: (2016)

Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability
por: Siotto, Mariacristina, et al.
Publicado: (2019)

Functional and structural connectivity substrates of cognitive performance in relapsing remitting multiple sclerosis with mild disability
por: Has Silemek, Arzu Ceylan, et al.
Publicado: (2020)

Evaluation of S100A12 and Apo-A1 plasma level potency in untreated new relapsing–remitting multiple sclerosis patients and their family members
por: Samangooei, Mahsa, et al.
Publicado: (2022)

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
por: Yavari, Fatemeh, et al.
Publicado: (2021)

Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2022)

Atypical parkinsonism and self‐mutilation: A new lens on the old concept
por: Salari, Mehri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0f106qbi7cmptsv71si10roqc3